Skip to main content
OpenTrials
Completed

NCT Number: NCT02069665

Effectiveness Study of Integrative Treatment for Pediatric Pneumonia

The purpose of this study is to evaluate the effectiveness of traditional Chinese medicine for treatment of pediatric pneumonia. It is a multicenter randomized controlled trial.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 month–59 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Affiliated Children's Hospital of Capital University of Medical Sciences, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

The retrospective case study has been finished at the National clinical research base of traditional Chinese medicine for major disease pediatric pneumonia, and the research center organized the field training of prospective-study to coordinated units. Based on the primary statistical outcomes of retrospective case study and the discussion around prospective-study during the training, investigators found it difficult to include simplex viral infection, therefore, investigators revised the inclusion criteria and treatment protocol of the pragmatic randomized controlled trial.

The block randomization is used in this trial. Random numbers are generated by SPSS software. Statistical analysis staff and those who perform the follow-up are blinded. Sample size calculation was performed, which was 369, and considering drop-out or withdrawal, investigators plan to enroll 450 patients (300 in experimental group, 150 in control).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • children, aged 6 months to 59 months old, diagnosed as pneumonia according to western medicine diagnostic criteria;
  • diagnosed as TCM pneumonia with gasp-cough, meeting wind-heat blocking lungs pattern (feng re bi fei zheng), and phlegm-heat blocking lungs pattern (tan re bi fei zheng);
  • disease progression within 72 hours;
  • those whose guardians understood and assigned the informed consent;

Exclusion criteria

  • emergency pneumonia;
  • complicated with other Pulmonary Disorders attack other than pneumonia;
  • complicated with primary disease of heart (congenital heart disease, myocarditis, et al), liver (ALT, and AST ≥ 1.5 times of normal value ceiling), kidney (BUN > 8.2mmol/L, or serum CR > 104 µmol/L, et al) and blood system (anemia), and those with psychopathy;
  • allergic to interventional medications;
  • those who are participating or have participated in other clinical trials in 3 months.

Treatment and study plan

Fuxiong San

Other

external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily

Xiyanping injection

Drug

ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

Ribavirin Injection

Drug

ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.

Xiaoer Qingfei Heji (mixture)

Drug

children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;

Zhi Ke San

Drug

children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

Other names: herbal powder to relieve cough

Hua Tan San

Drug

children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;

Other names: herbal powder to remove phlegm

Guaifenesin Syrup

Drug

children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;

Other names: Guaifenesin, Methylephedrine and Chlorphenamine Syrup

Ibuprofen Suspension

Drug

taken under prescription

Other names: Motrin

Salbutamol

Drug

taken under prescription

Other names: β2-agonists

Primary outcomes

  1. Cured rate

    Time frame: Every day since receiving treatment, all together 10 days (times)

    Clinical symptoms and signs totally disappear, the period of lab tests return to normal is recorded.

  2. Effectiveness time window

    Time frame: Every day since receiving treatment, all together 10 days (times)

    days range from treatment is received to the effectiveness is observed, and symptoms disappear

Secondary outcomes

  1. TCM syndrome scores and effective rate

    Time frame: 10 days

    Total effective rate according to TCM syndrome differentiation and treatment, and single syndrome effective rate

  2. Effect in fever, cough, phlegm and gasp

    Time frame: 10 days

    temperature, fever frequency, fever lasting time, Ibuprofen Suspension dosing; cough severity; phlegm amount, color and nature; gasp frequency, severity, all to be measured

  3. Time of lung rales disappear completely

    Time frame: 10 days

    days are counted since receiving treatment, when the chest radiograph returns to normal

  4. Check-out time

    Time frame: 10 days

    days counted when the patient checks out

  5. Pulmonary disease incidence

    Time frame: 30 days

    unresolved pneumonia, chronic cough, cough variant asthma incidence in the follow-up

Other outcomes

  1. Direct medical cost

    Time frame: observed during treatment in 10 days

    Medical cost including hospital expenses, examine fee, medication fee, et al, related to treatment in hospital

Sponsors and collaborators

Lead sponsor

Liaoning University of Traditional Chinese Medicine

Other

Collaborators

  • Beijing University of Chinese Medicine

Registry information

Official study title

Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases

Important dates

Study start
2011
Primary completion
2013
Study completion
2013
First posted
Feb 24, 2014
Registry last updated
Feb 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.